Expression of mTOR and its relationship with prognosis of breast cancer:a Meta-analysis
10.13481/j.1671-587x.20160428
- VernacularTitle:哺乳动物雷帕霉素靶蛋白的表达及其与乳腺癌预后关系的 Meta 分析
- Author:
Xianfei DING
;
Xueliang ZHOU
;
Mengmeng DOU
;
Lifeng LI
;
Lina GUO
;
Feng WANG
;
Qingxia FAN
- Publication Type:Journal Article
- Keywords:
breast neoplasms;
mammalian target of rapamycin;
prognosis;
Meta-analysis
- From:
Journal of Jilin University(Medicine Edition)
2016;42(4):783-788
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the expression of mammalian target of rapamycin (mTOR)and its relationgship with the prognosis of breast cancer,and to provide evidence-based basis for the using of mTOR inhibitor in the treatment of breast cancer.Methods: A systemical literature search was conducted based on the following databases:PubMed,EMBbase,Cochrane Library,ISI Web of Science,and CNKI up to November 24,2015.The outcome measures were hazard ratio (HR)with 95% confidence interval (CI) for the association between the mTOR expression and the prognosis of patients with breast cancer.The primary end points including disease-free survival (DFS ), and overall survival (OS ). STATA 12.0 was used to conduct the statistical analysis. Results:A total of seven cohort studies,1 758 patients were included. The risk of recurrence and metastasis of the breast cancer patients with positive expression of mTOR was 2.05 times of the patients with negative expression of mTOR (HR= 2.05, 95% CI: 1.01 - 4.13,P = 0.003);the risk of death in the breast cancer patients with positive expression of mTOR was 2.63 times of the patients with negative expression of mTOR (HR = 2.63, 95%CI:1.45-4.80,P = 0.736).Conclusion:The positive expression of mTOR can significantly increase the recurrence,metastasis and death risk of the patients with breast cancer.
